Effect of CD2 Gene on Immune Infiltration in Tumor Microenvironment of Ovarian Cancer

doi:10.12280/gjfckx.20220985

Abstract

Abstract:

Objective: To investigate the role of CD2 gene on immune infiltration in ovarian cancer microenvironment. Methods: GEPIA online tool was used to retrieve the expression of CD2 gene in ovarian cancer, GEPIA and Kaplan-Meier plotter databases were used to analyze the value of CD2 gene in evaluating the prognosis of ovarian cancer. Co-expression gene network of CD2 gene in ovarian cancer was constructed by Coexpedia. The key genes were screened out according to the score, and the correlation between CD2 gene and key genes was further analyzed by GEPIA and cBioportal to speculate the expression of related genes in ovarian cancer and their value for prognosis assessment. TIMER was used to analyze the expression of CD2 and related genes in ovarian cancer and the relationship between CD2 and six kinds of immune cells in tumor microenvironment. Results: ①In TCGA, the expression of CD2 gene in tumor tissue of ovarian cancer was higher than that in normal ovarian tissue (P<0.05). ②Both GEPIA and Kaplan-Meier plotter suggested that patients with high expression of CD2 gene had longer overall survival (P<0.05). ③The co-expressed genes of CD2 gene are CD3D, LCK, ITK, CCL5, CD48, GZMK, PTPRC, TRAF31P3, SH2D1A, GZMA, CD247, CD52, IL10RA, CD3E, IKZF1, CD53, CD6, CXCR6 and CD3G. ④In order of the highest score, the top five key genes were screened out, namely CD3D, LCK, ITK, CCL5 and CD48. CD2 was positively correlated with the expression of CD3D, LCK, ITK, CCL5 and CD48 (P<0.05). ⑤TIMER analysis showed that CD2 gene was positively correlated with the infiltration of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages and dendritic cells in ovarian cancer (P<0.05). COX regression model suggested that the infiltration level of macrophages and neutrophils was positively correlated with the prognosis of patients, the infiltration level of CD4+ T cells was negatively correlated with the prognosis of patients(P<0.05). Conclusions: CD2 gene is highly expressed in ovarian cancer tissues, which may affect the prognosis of patients by affecting the infiltration of immune cells in tumor microenvironment.

Key words: Ovarian neoplasms, CD2 gene, Tumor microenvironment, B-lymphocytes, Macrophages, Dendritic cells

WANG Yi-xuan, ZHANG Shao-hua, WANG Zan-hong. Effect of CD2 Gene on Immune Infiltration in Tumor Microenvironment of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2023, 50(3): 290-296.

Figures/Tables 9

References 28

[1]	Lisio MA, Fu L, Goyeneche A, et al. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints[J]. Int J Mol Sci, 2019, 20(4):952. doi: 10.3390/ijms20040952. doi: 10.3390/ijms20040952
[2]	Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4):280-304. doi: 10.3322/caac.21559. doi: 10.3322/caac.21559
[3]	Li Q, Pan Y, Cao Z, et al. Comprehensive Analysis of Prognostic Value and Immune Infiltration of Chromobox Family Members in Colorectal Cancer[J]. Front Oncol, 2020, 10:582667. doi: 10.3389/fonc.2020.582667. doi: 10.3389/fonc.2020.582667
[4]	Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression[J]. Cancer Res, 2019, 79(18):4557-4566. doi: 10.1158/0008-5472.CAN-18-3962. doi: 10.1158/0008-5472.CAN-18-3962 pmid: 31350295
[5]	Bader JE, Voss K, Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy[J]. Mol Cell, 2020, 78(6):1019-1033. doi: 10.1016/j.molcel.2020.05.034. doi: S1097-2765(20)30355-5 pmid: 32559423
[6]	Chen Y, Meng Z, Zhang L, et al. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment[J]. Front Immunol, 2021, 12:664845. doi: 10.3389/fimmu.2021.664845. doi: 10.3389/fimmu.2021.664845
[7]	Binder C, Cvetkovski F, Sellberg F, et al. CD2 Immunobiology[J]. Front Immunol, 2020, 11:1090. doi: 10.3389/fimmu.2020.01090. doi: 10.3389/fimmu.2020.01090 pmid: 32582179
[8]	Matsui T, Connolly JE, Michnevitz M, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions[J]. J Immunol, 2009, 182(11):6815-6823. doi: 10.4049/jimmunol.0802008. doi: 10.4049/jimmunol.0802008 pmid: 19454677
[9]	Ghosh A, Marques-Piubelli ML, Wang X, et al. CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma[J]. Virchows Arch, 2022, 481(4):659-663. doi: 10.1007/s00428-022-03348-x. doi: 10.1007/s00428-022-03348-x
[10]	Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-W102. doi: 10.1093/nar/gkx247. doi: 10.1093/nar/gkx247
[11]	Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5):401-404. doi: 10.1158/2159-8290.CD-12-0095. doi: 10.1158/2159-8290.CD-12-0095 pmid: 22588877
[12]	Alam O. A single-cell-type transcriptomics map of human tissues[J]. Nat Genet, 2021, 53(9):1275. doi: 10.1038/s41588-021-00938-4. doi: 10.1038/s41588-021-00938-4 pmid: 34493863
[13]	Chandrashekar DS, Bashel B, Balasubramanya S, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses[J]. Neoplasia, 2017, 19(8):649-658. doi: 10.1016/j.neo.2017.05.002. doi: S1476-5586(17)30179-3 pmid: 28732212
[14]	Lánczky A, Györffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation[J]. J Med Internet Res, 2021, 23(7):e27633. doi: 10.2196/27633. doi: 10.2196/27633
[15]	Yang S, Kim CY, Hwang S, et al. COEXPEDIA: exploring biomedical hypotheses via co-expressions associated with medical subject headings (MeSH)[J]. Nucleic Acids Res, 2017, 45(D1):D389-D396. doi: 10.1093/nar/gkw868. doi: 10.1093/nar/gkw868
[16]	Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function[J]. Nucleic Acids Res, 2010, 38(Web Server issue):W214-W220. doi: 10.1093/nar/gkq537. doi: 10.1093/nar/gkq537
[17]	Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells[J]. Cancer Res, 2017, 77(21):e108-e110. doi: 10.1158/0008-5472.CAN-17-0307. doi: 10.1158/0008-5472.CAN-17-0307
[18]	McCloskey CW, Rodriguez GM, Galpin K, et al. Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics[J]. Cancers(Basel), 2018, 10(8):244. doi: 10.3390/cancers10080244. doi: 10.3390/cancers10080244
[19]	Odunsi K. Immunotherapy in ovarian cancer[J]. Ann Oncol, 2017, 28(suppl_8):viii1-viii7. doi: 10.1093/annonc/mdx444. doi: 10.1093/annonc/mdx444
[20]	Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer[J]. Ann Oncol, 2016, 27(Suppl 1):i11-i15. doi: 10.1093/annonc/mdw084. doi: 10.1093/annonc/mdw084
[21]	Arneth B. Tumor Microenvironment[J]. Medicina(Kaunas), 2019, 56(1):15. doi: 10.3390/medicina56010015. doi: 10.3390/medicina56010015
[22]	An Y, Yang Q. Tumor-associated macrophage-targeted therapeutics in ovarian cancer[J]. Int J Cancer, 2021, 149(1):21-30. doi: 10.1002/ijc.33408. doi: 10.1002/ijc.33408 pmid: 33231290
[23]	Wang C, Ma C, Gong L, et al. Macrophage Polarization and Its Role in Liver Disease[J]. Front Immunol, 2021, 12:803037. doi: 10.3389/fimmu.2021.803037. doi: 10.3389/fimmu.2021.803037
[24]	Lee W, Ko SY, Mohamed MS, et al. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum[J]. J Exp Med, 2019, 216(1):176-194. doi: 10.1084/jem.20181170. doi: 10.1084/jem.20181170
[25]	Chen F, Xu Y, Chen Y, et al. TIGIT enhances CD4+ regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model[J]. Cancer Med, 2020, 9(10):3584-3591. doi: 10.1002/cam4.2976. doi: 10.1002/cam4.2976
[26]	Zhang M, Shi M, Yu Y, et al. The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer[J]. Vaccines(Basel), 2022, 10(9):1451. doi: 10.3390/vaccines10091451. doi: 10.3390/vaccines10091451
[27]	Crean-Tate KK, Braley C, Dey G, et al. Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors[J]. J Ovarian Res, 2021, 14(1):55. doi: 10.1186/s13048-021-00797-x. doi: 10.1186/s13048-021-00797-x pmid: 33888137
[28]	Kim S, Han Y, Kim SI, et al. Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer[J]. Mol Carcinog, 2021, 60(5):297-312. doi: 10.1002/mc.23289. doi: 10.1002/mc.23289

影响因素	B	SE	Wald χ²	HR	95%CI	P
B细胞	-1.906	0.570	4.470	0.149	0.000~60.750	0.534
CD8+ T细胞	-3.238	0.700	81.438	0.039	0.001~1.643	0.089
CD4+ T细胞	-15.241	2.973	13.370	0.000	0.000~0.000	0.000
巨噬细胞	9.442	1.078	83.262	12 612.838	60.580~2 626 013.740	0.001
中性粒细胞	9.025	0.983	15.302	8 305.325	1.521~45 359 183.998	0.040
树突状细胞	-0.922	0.566	4.469	0.398	0.004~39.274	0.694

影响因素	B	SE	Wald χ²	HR	95%CI	P
B细胞	-1.906	0.570	4.470	0.149	0.000~60.750	0.534
CD8+ T细胞	-3.238	0.700	81.438	0.039	0.001~1.643	0.089
CD4+ T细胞	-15.241	2.973	13.370	0.000	0.000~0.000	0.000
巨噬细胞	9.442	1.078	83.262	12 612.838	60.580~2 626 013.740	0.001
中性粒细胞	9.025	0.983	15.302	8 305.325	1.521~45 359 183.998	0.040
树突状细胞	-0.922	0.566	4.469	0.398	0.004~39.274	0.694